Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202447 · ClinicalTrials.gov registry record · Phase 1
Phase 1 of EC1169 In Patients With Recurrent MCRPC
A Phase 1 study of Prostate Cancer, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT02202447: Completed Phase 1 study of Prostate Cancer, sponsored by Endocyte.
NCT02202447 is a Phase 1 study of Prostate Cancer that has completed, run by Endocyte. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02202447, a Phase 1 study of Prostate Cancer, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body). All patients will receive EC1169. As a secondary objective in Part A: To explore the relationships between baseline PSMA expression (tumor and patient level) as measured by 99mTc-EC0652 scans and the antitumor activity of EC1169. As an exploratory objective in Part B: To assess EC0652 as a predictive biomarker for the efficacy of EC1169 by comparing PSMA-positive and PSMA-negative lesions for response.
Primary Outcome
Review to see if there are any (Dose Limiting Toxicities) seen in cycle 1.
Conditions Studied
Interventions
- DRUG EC1169
- OTHER EC0652
Study Locations (6)
Arizona
- Scottsdale Healthcare Clinical Trials at the Virginia G. Piper Cancer Center - Scottsdale
Connecticut
- Yale Cancer Center - New Haven
Louisiana
- Tulane Cancer Center - New Orleans
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-11-29 |
| Phase | Phase 1 |
What the finished NCT02202447 record still lists
NCT02202447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which EC1169 is the first listed.
NCT02202447 lists 6 locations in 6 states (Arizona, Connecticut, Louisiana).
Frequently Asked Questions
What is clinical trial NCT02202447 about?
NCT02202447 is a clinical study titled "Phase 1 of EC1169 In Patients With Recurrent MCRPC". The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body). All patients will rece...
What is the current status of trial NCT02202447?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-05. Estimated completion is 2018-11-29.
What conditions does trial NCT02202447 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02202447?
The interventions under investigation include: EC1169 (DRUG), EC0652 (OTHER).
Who is sponsoring clinical trial NCT02202447?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202447 being conducted?
This trial has 6 study locations across Arizona, Connecticut, Louisiana, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02202447's enrollment target sits among peer trials
40 526th of 735 higher than 201 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia